Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abvc Biopharma (ABVC) Share-based Compensation (2018 - 2025)

Historic Share-based Compensation for Abvc Biopharma (ABVC) over the last 12 years, with Q3 2025 value amounting to $1.1 million.

  • Abvc Biopharma's Share-based Compensation rose 40332.99% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.1 million, marking a year-over-year increase of 5343.43%. This contributed to the annual value of $2.8 million for FY2024, which is 20715.2% up from last year.
  • Latest data reveals that Abvc Biopharma reported Share-based Compensation of $1.1 million as of Q3 2025, which was up 40332.99% from $1.6 million recorded in Q2 2025.
  • In the past 5 years, Abvc Biopharma's Share-based Compensation registered a high of $4.7 million during Q1 2022, and its lowest value of -$507009.0 during Q4 2023.
  • Over the past 5 years, Abvc Biopharma's median Share-based Compensation value was $363079.0 (recorded in 2024), while the average stood at $995074.8.
  • Per our database at Business Quant, Abvc Biopharma's Share-based Compensation soared by 63422000.0% in 2021 and then crashed by 12677.92% in 2023.
  • Abvc Biopharma's Share-based Compensation (Quarter) stood at $4.4 million in 2021, then crashed by 56.77% to $1.9 million in 2022, then plummeted by 126.78% to -$507009.0 in 2023, then skyrocketed by 171.61% to $363079.0 in 2024, then skyrocketed by 212.94% to $1.1 million in 2025.
  • Its last three reported values are $1.1 million in Q3 2025, $1.6 million for Q2 2025, and $48773.0 during Q1 2025.